ちょんまげ院長のアロハ日記

ちょんまげ院長

プロフィール

新村 浩明(しんむら ひろあき) Hiroaki Shimmura

公益財団法人ときわ会 常磐病院の院長やってます。アロハとチョンマゲをこよなく愛する泌尿器科医です。
富山県出身
E--mail：shimmura@tokiwa.or.jp
ときわ会ホームページ：http://www.tokiwa.or.jp/

平成5年 富山大学医学部卒
平成5年 東京女子医科大学泌尿器科入局
平成17年9月 ときわ会 いわき泌尿器科病院
平成23年6月 ときわ会 常磐病院
平成27年9月 ときわ会 常磐病院　院長就任
●日本泌尿器科学会 専門医、指導医
●日本透析医学会 専門医、指導医
●日本臨床腎移植学会 認定医
●日本核医学会 PET 核医学認定医
●日本がん治療認定医機構 がん治療認定医
●日本泌尿器内視鏡学会 泌尿器腹腔鏡技術認定医
●日本内視鏡外科学会 技術認定医

論文業績

  1. Nomura S, Matsuzaki Y, Sato Y, Takasaki J, Sonoda Y, Shimmura H, Kodama Y. A Comparative Survival Analysis Between Evacuees and Nonevacuees Among Dialysis Patients in Fukushima Prefecture After Japan's 2011 Fukushima Nuclear Incident. Disaster Med Public Health Prep. 2019 May 27:1-7.
  2. Kanemoto Y, Tanimoto T, Shimmura H. Modified Clown Therapy using Traditional Japanese-style costumes for Elderly Patients in Post-disaster Fukushima. QJM. 2019 Feb 18.
  3. Yamashita K, Shimmura H, Tokiwa S, Kato S. Painless vascular leiomyoma found after incision of the vaginal wall: A case report. Urol Case Rep. 2017 Dec 16;17:19-21.
  4. Tanimoto T, Tsuda K, Oshima K, Mori J, Shimmura H. Carfilzomib for relapsed or refractory multiple myeloma. Lancet Oncol. 2018 Jan;19(1)
  5. Tokiwa S, Shimmura H, Nomura S, Watanabe R, Kurita M, Yoshida N, Yamashita K, Nishikawa Y, Kouzmenko A, Kato S. Degarelix treatment is compatible with diabetes and antithrombotic therapy in patients with prostate cancer. Res Rep Urol. 2017 Dec 6;9:225-232.
  6. Tanimoto T, Oshima K, Tsuda K, Mori J, Shimmura H. Rituximab and autologous stem-cell transplantation for high-risk diffuse large B-cell lymphoma. Lancet Oncol. 2017 Oct;18(10):e557.
  7. Tanimoto T, Tsuda K, Kurokawa T, Mori J, Shimmura H. Essential medicines for universal health coverage. Lancet. 2017 May 13;389(10082):1880-1881.
  8. Sonoda Y, Higuchi A, Morita T, Mori J, Shimmura H. Intensive blood pressure lowering. Lancet. 2016 Jun 4;387(10035):2291.
  9. Shimmura H, Tsubokura M, Kato S, Akiyama J, Nomura S, Mori J, Tanimoto T, Abe K, Sakai S, Kawaguchi H, Tokiwa M. Whole body counter assessment of internal radiocontamination in patients with end-stage renal disease living in areas affected by the Fukushima Daiichi nuclear power plant disaster: a retrospective observational study. BMJ Open. 2015 Dec 7;5(12):e009745.
  10. Akiyama J, Kato S, Tsubokura M, Mori J, Tanimoto T, Abe K, Sakai S, Hayano R, Tokiwa M, Shimmura H. Minimal Internal Radiation Exposure in Residents Living South of the Fukushima Daiichi Nuclear Power Plant Disaster. PLoS One. 2015 Oct 20;10(10):e0140482.
  11. Hayano RS, Tsubokura M, Miyazaki M, Ozaki A, Shimada Y, Kambe T, Nemoto T, Oikawa T, Kanazawa Y, Nihei M, Sakuma Y, Shimmura H, Akiyama J, Tokiwa M.Whole-body counter surveys of over 2700 babies and small children in and around Fukushima Prefecture 33 to 49 months after the Fukushima Daiichi NPP accident. Proc Jpn Acad Ser B Phys Biol Sci. 2015;91(8):440-6.
  12. Shimmura H, Kawaguchi H, Tokiwa M, Tanabe K. Impact of the Great Eastern Japan Earthquake on transplant renal function in Iwaki city, Fukushima. Transplant Proc. 2014;46(2):613-5.
  13. Kobayashi H, Tanaka Y, Shimmura H, Minato N, Tanabe K. Complete remission of lung metastasis following adoptive immunotherapy using activated autologous gammadelta T-cells in a patient with renal cell carcinoma. Anticancer Res. 2010 Feb;30(2):575-9.
  14. Shimmura H, Tanabe K, Habiro K, Abe R, Toma H. Combination effect of mycophenolate mofetil with mizoribine on cell proliferation assays and in a mouse heart transplantation model. Transplantation. 2006 Jul 27;82(2):175-9.
  15. Shimmura H, Tanabe K, Ishida H, Miyamoto N, Tokumoto T, Ishikawa N, Toma H. Long-term results of living kidney transplantation from HLA-identical sibling donors under calcineurin inhibitor immunosuppression. Int J Urol. 2006 May;13(5):502-8.
  16. Shimmura H, Tanabe K, Ishida H, Tokumoto T, Ishikawa N, Miyamoto N, Shirakawa H, Setoguchi K, Nakajima I, Fuchinoue S, Teraoka S, Toma H. Lack of correlation between results of ABO-incompatible living kidney transplantation and anti-ABO blood type antibody titers under our current immunosuppression. Transplantation. 2005 Oct 15;80(7):985-8.
  17. Habiro K, Shimmura H, Kobayashi S, Kotani M, Ishida Y, Tanabe K, Toma H, Abe R. Effect of inflammation on costimulation blockade-resistant allograft rejection. Am J Transplant. 2005 Apr;5(4 Pt 1):702-11.
  18. Shimmura H, Tanabe K, Tokumoto T, Ishida H, Ishikawa N, Miyamoto N, Shimizu T, Shirakawa H, Setoguchi K, Toma H. Impact of positive PRA on the results of ABO-incompatible kidney transplantation. Transplant Proc. 2004 Sep;36(7):2169-71.
  19. Shimmura H, Tanabe K, Tokumoto T, Ishida H, Ishikawa N, Miyamoto N, Shimizu T, Shirakawa H, Setoguchi K, Teraoka S, Toma H. Impact of HLA-identity on results of ABO-incompatible living kidney transplantation. Transplant Proc. 2004 Sep;36(7):2172-4.
  20. Shimmura H, Tanabe K, Tokumoto T, Ishida H, Ishikawa N, Miyamoto N, Shimizu T, Shirakawa H, Setoguchi K, Teraoka S, Toma H. Analysis of cause of death with a functioning graft: a single-center experience. Transplant Proc. 2004 Sep;36(7):2026-9.
  21. Toma H, Tanabe K, Tokumoto T, Shimizu T, Shimmura H. Time-dependent risk factors influencing the long-term outcome in living renal allografts: donor age is a crucial risk factor for long-term graft survival more than 5 years after transplantation. Transplantation. 2001 Sep 15;72(5):940-7.
  22. Shimmura H, Tanabe K, Ishikawa N, Tokumoto T, Toda F, Toma H. Discontinuation of immunosuppressive antimetabolite for parvovirus B19-associated anemia in kidney transplant patients. Transplant Proc. 2000 Nov;32(7):1967-70.
  23. Shimmura H, Tanabe K, Ishikawa N, Tokumoto T, Toda F, Toma H. Effect of donor age and rejection episodes on hypophosphatemia in long-term kidney transplant patients. Transplant Proc. 2000 Nov;32(7):1905-6.
  24. Ichikura H, Tanabe K, Tokumoto T, Shimuzu T, Ishikawa N, Harano M, Inui M, Manu M, Ito S, Shimmura H, Okuda H, Yagisawa T, Fuchinoue S, Toma H. Conversion of renal transplant immunosuppression from tacrolimus (FK 506) to cyclosporine: a single center experience. Transplant Proc. 2000 Nov;32(7):1733-5.
  25. Shimmura H, Tanabe K, Ishikawa N, Tokumoto T, Fuchinoue S, Takahashi K, Toma H, Agishi T. Removal of anti-A/B antibodies with plasmapheresis in ABO-incompatible kidney transplantation. Ther Apher. 2000 Oct;4(5):395-8.
  26. Shimmura H, Tanabe K, Ishikawa N, Tokumoto T, Takahashi K, Toma H. Role of anti-A/B antibody titers in results of ABO-incompatible kidney transplantation. Transplantation. 2000 Nov 15;70(9):1331-5.
  27. Shimmura H, Tanabe K, Ishikawa N, Kanematsu A, Tokumoto T, Oshima T, Fuchinoue S, Toma H. Influence of donor renal reserve on the long-term results of living kidney transplantation from elderly donors. Transplant Proc. 1999 Nov;31(7):2874-6.
  28. Shimmura H, Ishikawa N, Tanabe K, Tokumoto T, Ohsima T, Fuchinoue S, Ota K, Toma H. Angiographic embolization in patients with renal allograft arteriovenous fistula. Transplant Proc. 1998 Nov;30(7):2990-2.